<!doctype html>
<html>
	<head>
		<meta charset="utf-8">
		<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no">

		<title>Baxter International Existing Security Report</title>

		<link rel="stylesheet" href="css/reveal.css">
		<link rel="stylesheet" href="css/theme/night.css">

		<!-- Theme used for syntax highlighting of code -->
		<link rel="stylesheet" href="lib/css/zenburn.css">

		<!-- Printing and PDF exports -->
		<script>
			var link = document.createElement( 'link' );
			link.rel = 'stylesheet';
			link.type = 'text/css';
			link.href = window.location.search.match( /print-pdf/gi ) ? 'css/print/pdf.css' : 'css/print/paper.css';
			document.getElementsByTagName( 'head' )[0].appendChild( link );
		</script>
	</head>
	<body>
		<div class="reveal">

			<!-- Any section element inside of this container is displayed as a slide -->
			<div class="slides">
				<section data-background="images/sif.png">
					<img width="650" height="238" data-src="images/baxter.jpg" alt="Baxter Logo">
					<p>
						<small><font color="black">Matt Jarnevic</font></small>
					</p>
				</section>

				<section data-background="images/sif.png">
					<section>
					<h2>Contents</h2>
					<ul>
						<li>Business</li>
						<li>Industry</li>
						<li>Outside Influences</li>
						<li>Sources of Growth</li>
						<li>Fundamental Analysis</li>
						<li>Role in Portfolio and Recommendation</li>
						<br><br><br>
					</ul>
					</section>
				</section>
				
				<section data-background="images/sif.png">
					<section>
						<h2>Business</h2>
					</section>
					<section>
						<h2>Description</h2>
						<p>
						Sector: Health Care <br>
						Industry: Medical Instruments &amp; Equipment
						</p>
						<p>Baxter International Inc. is an American health care company 
						headquartered in Deerfield, Illinois. The company primarily focuses on 
						products to treat hemophilia, kidney disease, immune disorders and other 
						chronic and acute medical conditions.</p><br><br>
					</section>
					<section>
						<h2>Ownership</h2>
							<p>Publicly traded corporation. <br>
							Its three largest share holders include: 
							<p class="fragment"><font color="#a0914d">Vanguard Total Stock Mkt Idx (2.40%)</font></p>
							<p class="fragment"><font color="#3b3c87">Vanguard 500 Index Inv (1.68%)</font></p>
							<p class="fragment"><font color="#a0914d">Fidelity Contrafund (1.59%)</font></p>
						</p>
						<br><br><br><br>
					</section>
					<section>
						<h2>Market Share</h2>
							<p>4.5% of the market share
					<table>
						<thead>
							<tr>
								<th>Company Name</th>
								<th>Revenues</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td>Johnson &amp; Johnson</td>
								<td>76,450,000,000</td>
							</tr>
							<tr>
								<td>3M Co</td>
								<td>31,657,000,000</td>
							</tr>
							<tr>
								<td>Abbott Laboratories</td>
								<td>27,390,000,000</td>
							</tr>
							<tr>
								<td>Danaher Corp</td>
								<td>18,329,700,000</td>
							</tr>
							<tr>
								<td>Stryker Corp</td>
								<td>12,444,000,000</td>
							</tr>
							<tr>
								<td>Becton, Dickinson &amp; Co</td>
								<td>12,093,000,000</td>
							</tr>
							<tr>
								<td>Baxter International Inc.</td>
								<td>10,561,000,000</td>
							</tr>
						</tbody>
					</table>
							</p>
						<br><br><br><br>
					</section>
				</section>
				
				<section data-background="images/sif.png">
					<section>
					<h2>Industry</h2>
					</section>
					<section>
					<p>
					They provide a broad portfolio of essential healthcare products 
					including: <br>
					</p>
					<p class="fragment"><font color="#a0914d">Sterile IV solutions</font></p>
					<p class="fragment"><font color="#3b3c87">Inhaled anesthetics</font></p>
					<p class="fragment"><font color="#a0914d">Acute and chronic dialysis therapies</font></p>
					<br><br><br><br>
					</section>
					<section>
					<small><p>While Baxter does not sell something new or innovative, they do have a slight
					advantage by participating in emerging markets.</p></small>
					<small><p>Their products are manufactured in nearly 20 countries and are currently 
					sold in over 100 countries.</p></small>
					<small><p> In 2017, the company generated approximately 60% of its revenues outside of
					the United States. </p></small><br><br><br><br>
					</section>
				</section>
				
				<section data-background="images/sif.png">
					<section>
					<h2>Outside Influences</h2>
					</section>
					<section>
					<h2>Positives</h2>
					<p>Normally this would not be a positive and it is a growing problem that needs to be solved</p>
					</section>
					<section>
					<img data-src="images/mcdonalds.jpeg" alt="McDonald's">
					</section>
					<Section>
					<img width=200% height=200% data-src="images/rates.jpg" alt="rising obesity rates">
					</section>
					<section>
					<small><p>If you are overweight or obese, you have a greater chance of developing diabetes or high blood pressure, which are the 
					leading causes of kidney disease and kidney failure.</p></small>
					<small><p>In fact, 20-40% of diabetes patients develop renal disease. And if their condition is left untreated, 
					they will require dialysis several times a week. </p></small>
					<small><p>The number of dialysis patients in these regions is also 
					expected to grow at a faster pace than in developed countries.</p></small>
					</section>
					<section>
					<img width=200% height=200% data-src="images/sales.png" alt="rising obesity rates">
					</section>
					<section>
					<h2>Negatives</h2>
					<p>Increasingly competetive and regulated environment</p>
					<p>Fluctuating foreign currency exchange rates</p>
					</section>
				</section>
				
				<section data-background="images/sif.png">
					<section>
					<h2>Sources of Growth</h2>
					</section>
					<section>
					<p> Baxterâ€™s broad and diversified portfolio of medical products that treat 
					life-threatening acute or chronic conditions and its global presence are core
					components for growth </p>
					</section>
					<section>
					<p>The company is focused on three strategies: 
					<p class="fragment"><font color="#a0914d">Optimizing its core portfolio globally</font></p>
					<p class="fragment"><font color="#3b3c87">Streamlining the cost structure and enhancing operational efficiency</font></p>
					<p class="fragment"><font color="#a0914d">Following a disciplined and balanced approach to capital allocation</font></p>
					</section>
					<Section>
					<h2>Core Optimization</h2>
					<small><p>Optimize its position in product areas where the 
					company has a stable, profitable business model</p>
					<p>Identify and alter 
					investments in products that have reached the end of their life cycles 
					or where market positions have evolved unfavorably</p> 
					<p>Continue to reallocate 
					capital to more promising opportunities</p></small>
					</section>
					<Section>
					<h2>Streamlining</h2>
					<small><p>Optimize its cost structure</p>
					<p>Ensure it is committing resources to the highest value uses</p></small> 
					</section>
					<Section>
					<h2>Capital Allocation</h2>
					<small><p>Reinvest in the business</p>
					<p>Return capital to stockholders through stock dividends</p> 
					<p>Share repurchases</p></small>
					</section>
				</section>
				
				<section data-background="images/sif.png">
					<section>
					<h2>Fundamental Analysis</h2>
					</section>
					<section>
					<table>
						<thead>
							<tr>
								<th>Financial Data</th>
								<th>2017</th>
								<th>2016</th>
								<th>2015</th>
								<th>2014</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td>Rev. Growth</td>
								<td>2.14%</td>
								<td>-33.6%</td>
								<td>13.87%</td>
								<td>33.55%</td>
							</tr>
							<tr>
								<td>Gross Margin</td>
								<td>51.45%</td>
								<td>44.22%</td>
								<td>42.74%</td>
								<td>41.59%</td>
							</tr>
							<tr>
								<td>Profit Margin</td>
								<td>16.39%</td>
								<td>21.37%</td>
								<td>23.30%</td>
								<td>9.71%</td>
							</tr>
							<tr>
								<td>Asset Turnover</td>
								<td>0.72</td>
								<td>0.41</td>
								<td>0.42</td>
								<td>0.42</td>
							</tr>
							<tr>
								<td>Assets/Equity</td>
								<td>2.92</td>
								<td>2.97</td>
								<td>3.20</td>
								<td>2.36</td>
							</tr>
							<tr>
								<td>ROE</td>
								<td>34.40%</td>
								<td>26.13%</td>
								<td>30.12%</td>
								<td>11.41%</td>
							</tr>
						</tbody>
					</table>
					</section>
					<Section>
					<table>
						<thead>
							<tr>
								<th>Valuation Date</th>
								<th></th>
								<th>10/3/2018</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td>Component</td>
								<td>Method</td>
								<td>Value/Share</td>
							</tr>
							<tr>
								<td></td>
								<td>Discount Dividend Model</td>
								<td>82.58</td>
							</tr>
							<tr>
								<td></td>
								<td>Multi Stage</td>
								<td>34.33</td>
							</tr>
							<tr>
								<td></td>
								<td>FCF</td>
								<td>78.76</td>
							</tr>
							<tr>
								<td></td>
								<td>Enterprise Value</td>
								<td>77.53</td>
							</tr>
							<tr>
								<td>Evaluated Share Price</td>
								<td></td>
								<td>77.53</td>
							</tr>
							<tr>
								<td>Ke</td>
								<td></td>
								<td>8.45%</td>
							</tr>
							<tr>
								<td>Market price as of Valuation Date</td>
								<td></td>
								<td>77.80</td>
							</tr>

							<tr>
								<td>Dividend Yield</td>
								<td></td>
								<td>0.98%</td>
							</tr>
						</tbody>
					</table>
					</section>
					<section>
					<img width=200% height=200% data-src="images/enterprise.png" alt="rising obesity rates">
					</section>
				</section>
				<section data-background="images/sif.png">
					<section>
					<h2>Role in Portfolio and Recommendation</h2>
					</section>
					<section>
					<p>Baxter makes up just under 2% of our portfolio</p>
					<p>It has a beta of 0.89</p>
					<p>It's dividend yield is just under 1%, but has been steadily growing</p>
					</section>
					<section>
					<p>Both Stryker and Medtronic are in the medical devices industry and have global presences</p>
					<p>Baxter's products vary from either of theirs and since Baxter is mainly in emerging markets,
					it has solid footing and still provides diversity in our portfolio</p>
					<p>I recommend we continue to hold Baxter, especially considering it's stock price increased 130% over the last three years</p>
					</section>
				</section>
				<section data-background="images/sif.png">
					<h2>Questions?</h2>
				</section>
				<section data-background="images/sif.png">
					<h2>Appendix</h2>
					<a href="#/2/3">Market Share</a>
				</section>
			</div>

		</div>

		<script src="lib/js/head.min.js"></script>
		<script src="js/reveal.js"></script>

		<script>
			// More info about config & dependencies:
			// - https://github.com/hakimel/reveal.js#configuration
			// - https://github.com/hakimel/reveal.js#dependencies
			Reveal.initialize({
				dependencies: [
					{ src: 'plugin/markdown/marked.js' },
					{ src: 'plugin/markdown/markdown.js' },
					{ src: 'plugin/notes/notes.js', async: true },
					{ src: 'plugin/highlight/highlight.js', async: true, callback: function() { hljs.initHighlightingOnLoad(); } }
				]
			});
		</script>
	</body>
</html>
